Janssen Biotech gets rights to Pharmacyclics' PCI32765
Johnson & Johnson’s Janssen Biotech Inc. (a division of Janssen Pharmaceutical Cos.) has licensed worldwide development and marketing rights to Pharmacyclics Inc.’s (cancer and immune-mediated disease therapeutics) PCI32765, a first-in-class Bruton’s tyrosine kinase inhibitor in Phase II for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.